SURGE

CJC-1295 + Ipamorelin

2mg+2mg/vial

Two peptides studied together as growth hormone secretagogues, compounds that act on the body's own GH-release machinery rather than supplying growth hormone directly. CJC-1295 is a modified analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a selective ghrelin receptor agonist studied for its narrow hormonal profile compared to older compounds in its class. What the research explores: GHRH receptor signaling and pulsatile GH release patterns, ghrelin receptor activation pathways, and the combined effect of pairing a long-acting GHRH analog with a short-acting ghrelin mimetic to approximate the body's natural release rhythm. What it isn't: synthetic HGH. The mechanism under study is stimulation of the pituitary's own hormone production, a distinction the research literature treats as significant.

This information is provided for research purposes only and does not constitute medical advice. IRIX products are not for human or animal consumption.